Answers are grounded in this paper and cite their sources.
Vonoprazan, a potassium-competitive acid blocker, demonstrates more potent acid inhibition than proton pump inhibitors (PPIs). This study aimed to evaluate the effect of vonoprazan in patients with unproven gastroesophageal reflux disease (GERD) by comparing patients with vonoprazan-refractory heartburn with those with PPI-refractory heartburn.
No takes yet. Share an insight, caveat, or question.
Matsumura et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: